Navarra – July 2021– Medibiofarma S.L., a clinical-stage biotechnology company developing, as part of its portfolio of projects, a new disease-modifying therapy for the treatment of neurodegeneration and cognitive decline today announced the first subject dosed in the Phase 1 clinical trial of...
Navarra – July 2021– Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of cancer and non-cancer diseases today announced the first subject dosed in the Phase Ib clinical trial of MBF-118. This compound has successfully completed...
To provide the best experiences, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting, or withdrawing consent, may adversely affect certain features and functions.
